Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers.
Researchers from Beijing Pharscin Innobio Co. Ltd. presented the discovery and preclinical characterization of a novel highly selective poly (ADP-ribose) polymerase 7 (PARP7) inhibitor, HSN-002066, being developed for the treatment of cancer.
The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas.
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation.
Researchers from Beigene (Beijing) Co. Ltd. have disclosed preclinical data for BGB-B167, a first-in-class immunoglobulin G (IgG)-based bispecific antibody (bsAb) targeting 4-1BB and CEA, being developed for the treatment of advanced or metastatic solid tumors.
Insilico Medicine Inc. recently discussed the generative artificial intelligence (AI)-powered design of ISM-6331, a novel, potent, selective and non-covalent pan-TEAD inhibitor that blocks TEAD palmitoylation to suppress YAP/TAZ-TEAD transcriptional activity and shows strong antitumor activity in a preclinical model of Hippo pathway-dysregulated cancers and other solid cancers were discussed.
DXC-006 (Hangzhou DAC Biotechnology Co. Ltd.) is an antibody-drug conjugate (ADC) that targets CD56, a molecule involved in cell-cell adhesion and cell-matrix adhesion that is overexpressed in neuroblastoma, small-cell lung cancer and multiple myeloma, but less frequently expressed in normal tissues. DXC-006 consists of an anti-CD56 antibody (DXA-006) linked to the topoisomerase 1 (TOP1) inhibitor CPT-116 through a linker.
The discovery of a potent, selective and orally bioavailable serine/threonine-protein kinase PLK4 (STK18) inhibitor with synthetic lethality in TRIM7-amplified cancers was reported by Oric Pharmaceuticals Inc. at the ongoing AACR meeting in San Diego.
Researchers from Puhe Biopharma Co. Ltd. presented the discovery and preclinical evaluation of PH027-1, a novel small-molecule Werner syndrome protein (WRN) inhibitor targeting microsatellite instability high (MSI-H) tumors.